OMTRYG Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omtryg, and what generic alternatives are available?
Omtryg is a drug marketed by Osmotica Pharm Us and is included in one NDA.
The generic ingredient in OMTRYG is omega-3-acid ethyl esters type a. There are thirteen drug master file entries for this compound. Additional details are available on the omega-3-acid ethyl esters type a profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMTRYG?
- What are the global sales for OMTRYG?
- What is Average Wholesale Price for OMTRYG?
Summary for OMTRYG
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in OMTRYG? | OMTRYG excipients list |
| DailyMed Link: | OMTRYG at DailyMed |
US Patents and Regulatory Information for OMTRYG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osmotica Pharm Us | OMTRYG | omega-3-acid ethyl esters type a | CAPSULE;ORAL | 204977-001 | Apr 23, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
